addit
fl
uid
haemostasi
lipid
absorpt
lymphat
system
lymphoid
tissu
serv
major
host
immun
cell
immun
respons
evok
impair
function
immun
system
might
lead
seriou
diseas
often
treat
immunomodul
chapter
briefl
explor
physiolog
import
part
lymphat
system
gutassoci
lymphoid
tissu
galt
current
use
strategi
target
galt
immunomodul
enhanc
activ
andor
decreas
side
effect
discuss
strategi
rang
simpl
oral
coadministr
immunomodul
lipid
advanc
lipidbas
formul
polymerbas
nanoparticl
formul
prodrug
target
approach
success
increas
concentr
immunomodul
achiev
galt
importantli
enhanc
immunomodulatori
effect
therefor
target
immunomodul
galt
repres
promis
approach
treatment
diseas
immun
system
activ
involv
current
understand
lymphat
system
lymphoid
tissu
develop
centuri
fourth
centuri
bc
compon
lymph
system
particularli
auxiliari
lymph
node
fi
rst
describ
hippocr
vessel
contain
white
blood
howev
sixteenth
centuri
ad
italian
physician
aselli
succeed
describ
lymphat
system
gut
fed
dog
discoveri
made
accident
tri
observ
diaphragm
notic
network
vessel
contain
milki
white
fl
uid
later
name
lacteal
vessel
howev
aselli
suggest
vessel
deliv
content
liver
took
mani
decad
french
physician
pecquet
identifi
ed
thorac
duct
prove
duct
receiv
fl
ow
lacteal
discov
aselli
accur
anatom
descript
develop
later
use
wax
inject
uncov
part
system
includ
discoveri
lymph
nodul
mucou
membran
small
intestin
peyer
patch
pp
name
discover
johann
conrad
peyer
accur
function
descript
discov
structur
propos
public
william
hunter
research
suggest
research
lymphat
lacteal
structur
unit
one
larg
system
distribut
remot
part
bodi
inde
lymphat
system
thought
mere
drainag
system
fl
uid
protein
interstiti
space
back
blood
current
howev
lymphat
system
consid
central
role
pathogenesi
sever
diseas
cancer
viral
infect
parasit
infect
autoimmun
disord
fact
main
pathway
metastas
epitheli
origin
solid
tumour
colon
breast
lung
prostat
addit
lymphat
system
recognis
crucial
part
immun
system
invad
antigen
trap
process
present
immun
cell
consequ
immun
respons
evok
respons
import
protect
bodi
bacteri
viral
parasit
fungal
threat
well
growth
tumour
cell
defi
cienci
immun
respons
whether
inherit
acquir
weaken
bodi
defenc
mechan
hand
overreact
immun
respons
might
caus
lifethreaten
diseas
commonli
call
autoimmun
diseas
therefor
substanc
posit
neg
modifi
weak
overreact
immun
respons
respect
provid
novel
approach
treatment
disord
immun
system
central
role
substanc
collect
refer
immunomodul
last
decad
wit
use
immunomodul
promis
therapeut
agent
treatment
infecti
diseas
autoimmun
diseas
cancer
prevent
organ
transplant
reject
therapeut
effect
immunomodul
achiev
either
augment
suppress
activ
immun
cell
sinc
lymphat
system
major
host
immun
cell
focu
chapter
highlight
current
strategi
target
immunomodul
particular
cannabinoid
gutassoci
lymphoid
tissu
galt
mention
substanti
interest
develop
nineteenth
centuri
elucid
function
lymphat
system
function
summaris
follow
fluid
continu
escap
blood
capillari
surround
tissu
howev
signifi
cant
proport
fl
uid
reabsorb
venou
capillari
inde
four
litr
fl
uid
half
plasma
protein
extravas
day
turn
could
lead
circulatori
failur
increas
tissu
pressur
unrecov
lymphat
system
therefor
maintain
bodi
fl
uid
balanc
reabsorpt
extravas
fl
uid
protein
back
system
circul
intestin
lymphat
system
essenti
physiolog
role
absorpt
dietari
lipid
lipidsolubl
vitamin
fi
rst
step
absorpt
dietari
lipid
digest
micellar
solubilis
gastrointestin
lumen
happen
mainli
action
pancreat
lipasecolipas
complex
bile
salt
small
intestin
digest
product
lipid
hydrolysi
incorpor
mix
micel
promot
diffus
digest
lipid
apic
membran
enterocyt
insid
enterocyt
longchain
triglycerid
lct
resynthesis
longchain
fatti
acid
monoglycerid
mainli
action
acyltransferas
lct
assembl
apolipoprotein
b
apo
b
phospholipid
cholesterol
cholesterol
ester
form
larg
lipoprotein
lipid
core
chylomicron
cm
matur
cm
secret
exocytosi
basolater
membran
enterocyt
larg
particl
cm
pass
wall
vascular
capillari
absorb
lymph
lacteal
instead
presenc
lipid
form
cm
lymph
fl
uid
follow
highfat
meal
look
like
turbid
emuls
commonli
call
chyle
immun
system
defi
nite
organ
system
per
se
rather
popul
cell
distribut
organ
defend
bodi
potenti
invad
import
cell
involv
immun
respons
lymphocyt
lymphocyt
localis
lymphat
system
collect
fl
uid
plasma
protein
lymphat
system
also
pick
foreign
bodi
tissu
bodi
drain
along
lymph
region
lymph
node
immun
cell
initi
immun
respons
therefor
lymph
node
stand
checkpoint
examin
lymph
fl
uid
drain
bloodstream
lymph
usual
clear
colourless
fl
uid
drain
interstitium
addit
recov
fl
uid
plasma
protein
lymph
may
also
contain
lipid
immun
cell
hormon
bacteria
virus
cellular
debri
even
cancer
cell
substanti
differ
lymph
composit
aris
physiolog
andor
patholog
condit
tissu
lymph
drain
well
locat
along
lymphat
vessel
lymphat
system
bodi
second
circulatori
system
howev
unlik
close
structur
blood
vessel
lymphat
system
consist
unidirect
blindend
thinwal
capillari
vessel
lymph
driven
without
central
pump
lymphat
capillari
drain
affer
collect
vessel
pass
one
gather
lymph
node
lymph
fl
uid
pass
effer
collect
vessel
larger
trunk
fi
nalli
lymphat
duct
subsequ
duct
drain
lymph
system
circul
lymphat
organ
classifi
ed
primari
secondari
primari
lymphat
organ
includ
thymu
gland
bone
marrow
produc
matur
lymphocyt
identifi
respond
antigen
secondari
lymphat
organ
includ
lymph
node
spleen
mucosaassoci
lymph
tissu
malt
within
secondari
lymphat
organ
lymphocyt
initi
immun
respons
malt
distribut
throughout
mucou
membran
provid
defenc
mechan
wide
varieti
inhal
ingest
antigen
malt
categoris
accord
anatom
locat
bronchusassoci
lymphoid
tissu
balt
nasalassoci
lymphoid
tissu
nalt
salivari
gland
ductassoci
lymphoid
tissu
dalt
conjunctivaassoci
lymphoid
tissu
calt
lacrim
ductassoci
lymphoid
tissu
ldalt
gutassoci
lymphoid
tissu
galt
galt
consist
effector
immun
induct
site
former
repres
lymphocyt
distribut
throughout
lamina
propria
lp
intestin
epithelium
latter
involv
organis
tissu
mesenter
lymph
node
mln
pp
smaller
isol
lymphoid
follicl
ilf
author
howev
defi
ne
mln
separ
lymphat
organ
rather
part
galt
chapter
mln
includ
refer
galt
mesenter
lymph
node
mln
largest
gather
lymph
node
bodi
found
base
mesenteri
structur
mln
similar
peripher
lymph
node
divid
two
region
medulla
cortex
cortex
mainli
compos
tcell
area
bcell
follicl
within
tcell
area
circul
lymphocyt
enter
lymph
node
dendrit
cell
dc
present
antigen
tcell
lymph
contain
cell
antigen
chylomicron
collect
intestin
mucosa
reach
mln
via
affer
lymphat
lymph
fl
uid
subsequ
leav
mln
effer
lymphat
reach
thorac
duct
drain
blood
peyer
patch
pp
collect
lymphoid
nodul
distribut
mucosa
submucosa
intestin
consist
subepitheli
dome
area
bcell
follicl
dispers
tcell
area
singl
layer
epitheli
cell
call
follicleassoci
epithelium
fae
separ
lymphoid
area
pp
intestin
lumen
fae
permeat
specialis
enterocyt
call
microfold
cell
cell
consid
gate
transport
lumin
antigen
pp
isol
lymphoid
follicl
ilf
combin
lymphoid
cell
intestin
lp
ilf
structur
similar
pp
sens
compos
germin
centr
cover
fae
contain
mcell
howev
unlik
pp
ilf
lack
discret
tcell
area
although
function
complet
understood
ilf
thought
complementari
system
pp
induct
intestin
immun
noteworthi
galt
largest
lymphat
organ
human
bodi
contain
half
bodi
lymphocyt
galt
also
expos
antigen
part
bodi
form
commens
bacteria
alimentari
antigen
addit
invas
pathogen
intestin
immun
system
must
therefor
abl
distinguish
antigen
requir
protect
immun
respons
develop
state
immun
hyporespons
oral
toler
antigen
harmless
bodi
mechan
govern
process
involv
sampl
lumin
antigen
intestin
epithelium
dc
antigen
cross
epithelium
mcell
found
fae
pp
antigen
interact
dc
underli
subepitheli
dome
region
antigen
present
local
tcell
pp
dc
dc
also
migrat
drain
mln
present
antigen
local
lymphocyt
altern
pathway
antigen
transport
across
intestin
epitheli
cell
involv
receptormedi
transport
well
direct
sampl
lumen
dc
project
antigenload
dc
migrat
mln
affer
lymphat
present
antigen
tcell
subsequ
differenti
lymphocyt
migrat
mln
thorac
duct
blood
stream
eventu
accumul
mucosa
appropri
immun
respons
fig
gener
galt
could
target
effect
compart
andor
rout
therapeut
agent
deliv
system
circul
addit
dc
use
transepitheli
project
sampl
antigen
directli
lumen
dc
present
antigen
local
lymphocyt
migrat
mesenter
lymph
node
mln
lymphocyt
prime
achiev
high
local
concentr
galt
could
particular
import
pharmacolog
agent
immunomodul
exampl
cannabinoid
chemotherapeut
agent
antiinfect
agent
therebi
decreas
doserel
system
side
effect
well
system
dilut
lymphat
system
main
pathway
intestin
tumour
metastas
therefor
target
cytotox
drug
intestin
lymphat
could
provid
advantag
treatment
tumour
metastas
largest
lymphat
organ
galt
provid
valid
deliveri
target
antivir
agent
virus
spread
develop
within
lymphat
system
particular
import
human
immunodefi
cienci
viru
hiv
morbilliviru
canin
distemp
viru
sever
acut
respiratori
syndrom
sar
associ
coronaviru
hepat
b
hepat
c
increas
bioavail
lipophil
drug
oral
coadminist
lipid
vehicl
could
anoth
advantag
primarili
occur
result
enhanc
micellar
solubilis
drug
small
intestin
drugcm
associ
enterocyt
one
import
reason
intestin
lymphat
transport
avoid
hepat
fi
rstpass
metabol
loss
divert
absorpt
lipophil
drug
toward
intestin
lymphat
rather
portal
vein
extrem
import
drug
exhibit
signifi
cant
fi
rstpass
metabol
intestin
lymphat
transport
lipophil
drug
result
deliveri
drug
system
circul
cmassoci
form
might
attenu
pharmacokinet
andor
pharmacodynam
properti
miura
et
al
shown
oral
administr
lct
oliv
oil
enhanc
lymphocyt
transport
mesenter
lymphat
rat
tenfold
miura
et
al
also
demonstr
enhanc
lymphocyt
fl
ux
select
administr
longchain
mediumchain
fatti
acid
turn
secondari
assembl
cm
enterocyt
enhanc
absorpt
oral
administ
longchain
fatti
acid
coadministr
pluron
l
inhibitor
intracellular
cm
transport
secret
signifi
cantli
decreas
lymphocyt
transport
fig
moreov
effect
longchain
fatti
acid
particularli
monounsatur
fatti
acid
limit
augment
lymphocyt
fl
ux
also
stimul
lymphocyt
prolifer
precis
mechan
govern
effect
unclear
howev
mechan
involv
utilis
cm
phospholipid
fatti
acid
suggest
view
support
observ
calder
et
al
found
lymphocyt
lipoprotein
lipas
activ
abl
releas
fatti
acid
triglycerid
tg
present
cm
lowdens
lipoprotein
addit
studi
also
show
tg
rich
polyunsatur
fatti
acid
pufa
linol
acid
potent
inhibitor
lymphocyt
prolifer
vitro
effect
observ
use
monounsatur
oleic
acid
part
explain
clinic
benefi
ts
daili
administr
veget
oil
contain
linol
acid
patient
suffer
infl
ammatori
autoimmun
diseas
rheumatoid
arthriti
psoriasi
multipl
sclerosi
therefor
reason
conclud
target
immunomodul
galt
could
present
valid
treatment
strategi
wide
rang
seriou
diseas
list
top
market
oral
administ
drug
poorli
watersolubl
usual
associ
poor
absorpt
gut
low
bioavail
mani
biolog
activ
drug
also
highli
metabolis
abl
exert
benefi
cial
effect
also
reduc
bioavail
combin
poor
absorpt
high
fi
rstpass
metabol
creat
need
drug
deliveri
system
improv
absorpt
poorli
watersolubl
drug
also
protect
degrad
one
promis
strategi
address
issu
lbdd
simplest
method
target
drug
galt
coadministr
lipid
drug
oral
administr
lipid
chang
pharmacokinet
pharmacodynam
profi
le
drug
reduc
rate
gastric
empti
stimul
releas
bile
contain
surfact
bile
acid
phospholipid
gall
bladder
bile
acid
hydrophil
one
end
hydrophob
wherea
phospholipid
gener
one
hydrophil
tail
two
hydrophob
tail
two
fatti
acid
amphiphil
surfact
emulsifi
lipid
form
fi
ne
emuls
prevent
droplet
aggreg
back
larger
particl
emulsifi
cation
vastli
increas
surfac
area
lipid
provid
interfac
pancreat
lipasecolipas
complex
digest
digest
tg
pancreat
lipas
form
monoglycerid
fatti
acid
previous
describ
chapter
tg
cholesterol
cholesterol
ester
transport
cm
typic
vari
nm
diamet
leav
enterocyt
cm
unabl
enter
portal
circul
due
larg
size
enter
lymphat
instead
allow
passag
larg
particl
drug
exploit
transport
pathway
associ
fatti
acid
tg
aforement
step
end
insid
core
cm
due
hydrophob
natur
core
highli
lipophil
drug
good
candid
transport
via
pathway
drug
candid
intestin
lymphat
transport
classic
describ
partit
coeffi
cient
log
p
higher
tg
solubl
higher
mgml
recent
physicochem
properti
includ
notabl
drug
distribut
coeffi
cient
ph
log
exampl
immunomodulatori
drug
target
galt
coadministr
lipid
drug
investig
lipophil
cannabinoid
cb
receptor
agonist
immunomodulatori
effect
therapeut
benefi
ts
anim
model
multipl
sclerosi
cannabinoid
gener
group
chemic
compound
act
cannabinoid
receptor
report
immunomodulatori
effect
studi
trevaski
et
al
intestin
lymphat
transport
recoveri
collect
lymph
lymphocyt
assess
mesenter
lymph
ductcannul
rat
follow
intraduoden
infus
oleic
acid
studi
administ
lipid
formul
contain
either
mg
oleic
acid
author
conclud
proport
dose
recov
mesenter
lymph
lymphocyt
signifi
cantli
higher
fold
respect
follow
administr
compar
mg
oleic
acid
formul
although
lymphocyt
fl
ux
mesenter
lymph
elicit
low
mg
oleic
acid
high
lipid
formul
mg
oleic
acid
increas
lymphocyt
fl
ux
fi
vefold
thu
studi
coadministr
longchain
fatti
acid
affect
galt
lymphocyt
three
mechan
enhanc
drug
absorpt
intestin
lumen
stimul
intestin
lymphat
transport
drug
increas
lymphocyt
fl
ux
area
furthermor
trevaski
et
al
compar
lymphat
transport
model
lipophil
molecul
name
dichlorodiphenyltrichloroethan
ddt
halofantrin
ciclosporin
diazepam
insecticid
antimalari
immunosuppress
central
nervou
system
depress
drug
respect
magnitud
intestin
lymphat
transport
correl
lipophil
tg
solubl
drug
result
show
extent
intestin
lymphat
transport
enhanc
drug
coadminist
compar
mg
oleic
acid
drug
fig
dexanabinol
anoth
nonpsychotrop
synthet
cannabinoid
suggest
therapeut
immunomodulatori
effect
treatment
experiment
multipl
sclerosi
gershkovich
et
al
evalu
lymphat
transport
dexanabinol
follow
oral
administr
lctbase
formul
rat
author
found
concentr
dexanabinol
recov
mesenter
lymph
around
higher
plasma
studi
anoth
lipophil
cannabinoid
found
higher
concentr
mesenter
lymph
versu
plasma
fi
nding
suggest
administr
lipophil
cannabinoid
lct
promis
target
strategi
galt
emuls
defi
ned
mixtur
two
immisc
liquid
fig
pharmaceut
applic
emuls
gener
made
three
compon
oil
surfact
water
hydrophilelipophil
balanc
compon
determin
whether
result
emuls
oil
droplet
water
oilinwat
two
main
pathway
uptak
drug
deliveri
system
intestin
water
droplet
oil
waterinoil
micel
oili
dispers
isotrop
solut
emulsifi
ed
upon
contact
water
last
mixtur
term
selfemulsifi
drug
deliveri
system
sedd
form
emuls
drug
deliv
way
protect
degrad
enzym
reliant
endogen
surfact
increas
surfac
area
absorpt
presenc
lipid
within
emuls
also
stimul
lymphat
transport
wellknown
exampl
immunomodulatori
agent
oral
deliv
microemuls
ciclosporin
polypeptid
drug
wide
use
prevent
reject
organ
transplant
suppress
activ
tcell
howev
ciclosporin
low
solubl
water
also
extens
metabolis
cytochrom
enzym
substanti
research
done
formul
ciclosporin
emuls
contain
lipid
microspher
milk
fat
globul
membran
sinc
approv
use
number
differ
formul
ciclosporin
becam
commerci
avail
mani
emuls
common
sandimmun
newer
formul
neoral
ciclosporin
import
candid
intestin
lymphat
transport
sinc
highli
metabolis
liver
metabolit
lower
immunosuppress
activ
sandimmun
origin
formul
ciclosporin
vastli
improv
bioavail
high
interand
intrapati
variabl
therefor
optimis
formul
consist
corn
oil
deriv
polyoxyl
hydrogen
castor
oil
name
neoral
test
result
predict
pharmacokinet
profi
le
extens
drug
absorpt
anoth
exampl
immunomodulatori
drug
target
galt
use
emulsionbas
formul
work
done
zhang
et
al
morin
xanthin
oxidas
inhibitor
shown
play
role
treatment
gout
formul
selfnanoemulsifi
drug
deliveri
system
snedd
improv
oral
absorpt
snedd
made
similar
compon
emuls
distinct
thermodynam
stabl
kinet
stabl
mean
emulsifi
cation
snedd
affect
temperatur
dilut
emuls
separ
differ
phase
prolong
storag
work
zhang
et
al
conjug
phospholipid
complex
morin
addit
incorpor
snedd
increas
intestin
permeabl
examin
intestin
absorpt
lymphat
transport
snedd
compar
conjug
drug
free
drug
group
show
snedd
found
galt
oral
administr
particularli
segment
closer
ileum
due
presenc
pp
mcell
liposom
close
spheric
structur
consist
least
one
phospholipid
bilay
rang
nm
much
like
phospholipid
bilay
capabl
contain
aqueou
phase
within
see
fig
mention
earlier
amphiphil
natur
phospholipid
allow
hold
hydrophil
contain
within
aqueou
phase
liposom
hydrophob
incorpor
bilay
membran
drug
drug
incorpor
liposom
also
protect
degrad
increas
therapeut
effi
caci
reduc
side
effect
liposom
releas
content
upon
degrad
lysosom
fusion
anoth
lipid
bilay
cell
membran
phagocyt
liposom
membran
extrem
modifi
abl
shown
deliv
encapsul
drug
wide
number
stimuli
ph
temperatur
redox
potenti
magnet
ultrasound
light
although
liposom
also
shown
success
target
differ
part
lymphat
system
follow
variou
rout
administr
subcutan
pulmonari
intramuscular
inject
section
focu
liposom
target
galt
follow
oral
administr
liposom
larg
enter
intestin
blood
capillari
pore
size
nm
therefor
enter
lymphat
instead
liposom
use
deliveri
protein
dna
perri
et
al
incorpor
plasmid
dna
encod
small
region
hepat
b
surfac
antigen
liposom
studi
immunis
confer
oral
administr
mice
compar
nake
dna
mice
receiv
dna
deliv
via
liposom
show
higher
iga
respons
group
went
studi
gene
express
mice
oral
administr
liposom
contain
plasmid
dna
encod
green
fl
uoresc
protein
found
liposom
deliveri
plasmid
dna
yield
much
higher
gene
express
drain
mesenter
lymph
node
mice
given
nake
plasmid
dna
author
conclud
liposom
could
use
agent
lymphat
deliveri
dna
masuda
et
al
incorpor
ovalbumin
model
antigen
liposom
oral
deliveri
examin
abil
induc
oral
toler
mice
ovalbumin
liposom
differ
composit
success
suppress
prolif
respons
poplit
lymph
node
cell
mice
suggest
liposom
taken
lymphat
induc
toler
ovalbumin
effect
ovalbumin
administ
aqueou
suspens
research
focus
deliveri
antigen
encapsul
liposom
lymphat
via
oral
rout
nanoparticl
particl
smaller
nm
size
use
deliveri
drug
galt
via
uptak
ilf
pp
mention
previous
chapter
although
exact
mechan
uptak
unclear
mani
exampl
nanoparticul
drug
deliveri
system
use
uptak
pathway
access
galt
exampl
discuss
section
discoveri
use
liposom
number
drawback
also
discov
drug
leakag
upon
storag
physic
instabl
aggreg
presenc
organ
solvent
residu
cytotox
lack
costeffect
method
highqual
product
drug
deliveri
system
base
natur
occur
lipid
develop
order
overcom
problem
lipid
nanoparticl
solid
matrix
high
drug
load
control
drug
releas
profi
le
better
longterm
stabil
easili
produc
emuls
liposom
larg
scale
one
type
lipidbas
nanoparticl
use
target
galt
solid
lipid
nanoparticl
solid
lipid
nanoparticl
sln
sln
usual
made
biocompat
lipid
surfact
tripalmitin
tristearin
poloxam
dioleoylphosphatidylethanolamin
tricaprin
tween
glyceryl
monostear
soya
lecithin
compon
solid
form
room
temperatur
therefor
stabl
provid
control
releas
specifi
c
drug
target
compar
liposom
sln
made
solid
lipid
core
stabilis
surfact
load
drug
would
fi
gap
fatti
acid
chain
lipid
core
fig
size
particl
type
formul
nm
diamet
allow
effi
cient
drug
uptak
intestin
lymphat
system
due
presenc
lipid
similar
size
cm
sln
also
taken
mcell
within
pp
repres
fig
one
exampl
use
sln
target
galt
work
paliw
et
al
group
load
methotrex
sln
made
glycerol
monostear
tristearin
compritol
ato
formul
administ
intraduoden
rat
methotrex
use
treatment
cancer
autoimmun
diseas
antagonis
folic
acid
metabol
drug
concentr
profi
le
plasma
lymph
determin
follow
intraduoden
administr
aqueou
methotrex
solut
four
type
sln
load
methotrex
author
found
sln
produc
lead
increas
drug
bioavail
prolong
releas
compar
aqueou
solut
threefold
higher
plasma
c
max
valu
addit
lymphat
uptak
methotrex
tenfold
higher
sln
compar
aqueou
solut
nanoparticl
fi
rst
develop
use
drug
deliveri
synthet
polym
prefer
choic
outer
coat
due
vari
puriti
natur
polym
polysaccharid
protein
time
potenti
interact
denatur
contain
drug
among
common
fdaapprov
polym
use
polymer
nanoparticl
polyglycol
acid
pga
polylact
acid
pla
pga
pla
consid
biocompat
sinc
degrad
glycol
lactic
acid
byproduct
metabol
pathway
bodi
polym
also
combin
copolym
poli
lactidecoglycosid
plga
ratio
pga
pla
plga
fi
netun
control
degrad
drug
releas
rate
polymer
nanoparticl
could
also
taken
pp
manner
similar
sln
kim
et
al
use
plga
nanoparticl
entrap
type
ii
collagen
cii
studi
abil
suppress
collageninduc
arthriti
mice
localis
nanoparticl
cii
circul
immunoglobulin
g
igg
target
cii
ciispecifi
c
tcell
prolifer
tumour
necrosi
factor
express
pp
drain
lymph
node
assess
singl
oral
administr
nanoparticl
contain
cii
group
found
ciicontain
nanoparticl
nm
diamet
persist
pp
day
administr
abl
reduc
incid
arthriti
half
reduc
igg
antibodi
half
versu
arbitrari
unit
express
also
upregul
pp
cell
treat
nanoparticl
downregul
drain
lymph
node
author
conclud
ciicontain
plga
nanoparticl
abl
suppress
develop
arthriti
well
autoimmun
respons
et
al
use
polyanhydrid
nanoparticl
anoth
biocompat
polym
load
peanut
extract
studi
oral
immunotherapi
peanut
allergi
raw
roast
peanut
protein
oral
administ
mice
level
differ
immunoglobulin
igg
ige
iga
secret
specifi
c
cytokin
relat
immun
respons
stimul
thelper
cell
assess
polyanhydrid
nanoparticl
contain
peanut
protein
abl
increas
product
igg
ige
iga
compar
free
protein
unload
nanoparticl
also
upregul
express
interleukin
immunosuppress
cytokin
reduc
infl
ammat
site
allerg
reaction
final
nanoparticl
also
shown
stimul
appropri
prophylact
thelper
cell
respons
twofold
higher
free
protein
effect
nanoparticl
sensitis
anim
examin
author
conclud
polyanhydrid
nanoparticl
could
use
food
oral
immunotherapi
prodrug
biorevers
precursor
drug
obstacl
attenu
therapeut
effi
caci
regard
galt
target
prodrug
modifi
drug
physicochem
properti
way
would
improv
deliveri
galt
achiev
mechan
involv
associ
prodrug
cm
assembl
enterocyt
therefor
prodrug
design
certain
physicochem
properti
particularli
log
high
lipid
solubl
intestin
lymphat
transport
enhanc
prodrug
coadminist
oral
lct
altern
prodrug
structur
incorpor
one
biochem
step
lipid
digest
process
exampl
prodrug
design
structur
similar
tg
phospholipid
circumst
prodrug
hydrolys
reacyl
eventu
incorpor
cm
lipoprotein
assembl
process
enterocyt
one
way
enhanc
lipophil
molecul
synthesi
ester
ether
amidelink
prodrug
larg
alkyl
moieti
han
et
al
describ
synthesi
lipophil
prodrug
promot
deliveri
mycophenol
acid
mpa
model
immunomodul
galt
oral
administr
oleic
acid
lipophil
mpa
log
p
increas
synthesi
longchain
ester
prodrug
log
p
longchain
amid
prodrug
log
p
oral
administr
mesenter
lymph
ductcannul
rat
result
increas
lymphat
transport
respect
compar
parent
compound
approach
enhanc
partit
alkyl
chain
prodrug
cm
therebi
promot
lymphat
transport
howev
least
lipophil
mediumchain
ester
prodrug
increas
recoveri
parent
compound
lymph
studi
tgmimick
prodrug
mpa
log
p
synthesis
tgmimick
prodrug
lead
increas
lymphat
transport
mechan
involv
incorpor
prodrug
tg
hydrolysisreacyl
cm
assembl
pathway
author
suggest
metabol
instabl
poor
absorpt
behind
low
lymphat
concentr
alkyl
prodrug
rel
tgmimick
prodrug
fig
current
high
number
immunomodul
show
remark
therapeut
benefi
ts
treatment
lifethreaten
immun
disord
deliv
galt
immunomodul
potenti
signifi
cantli
improv
futur
opportun
treat
disord
exampl
molecul
statin
wide
use
clinic
practic
cholesterollow
agent
anim
model
autoimmun
diseas
shown
statin
therapeut
immunomodulatori
effect
treatment
multipl
sclerosi
rheumatoid
arthriti
autoimmun
myocard
autoimmun
uveiti
howev
dose
statin
use
experi
higher
usual
use
human
thu
use
appropri
strategi
target
galt
statin
might
achiev
suffi
cient
concentr
produc
therapeut
immunomodulatori
effect
induc
less
system
advers
effect
offtarget
tissu
fact
research
use
lipidbas
formul
like
sedd
smedd
snedd
sln
nanostructur
lipid
carrier
nlc
mention
improv
oral
bioavail
statin
yet
neither
intestin
lymphat
transport
immunomodulatori
effect
assess
upon
administr
formul
therefor
tempt
suggest
statin
might
new
therapeut
applic
properli
target
galt
patient
autoimmun
diseas
import
group
potenti
therapeut
immunomodul
lipophil
cannabinoid
tetrahydrocannabinol
thc
cannabidiol
cbd
pharmacodynam
studi
shown
cannabinoid
broad
spectrum
therapeut
activ
anim
model
studi
immun
system
disord
report
thc
could
promis
drug
treatment
multipl
sclerosi
diabet
mellitu
allerg
asthma
cbd
also
show
therapeut
effi
caci
anim
model
rheumatoid
arthriti
diabet
mellitu
allerg
asthma
thc
cbd
highli
lipophil
molecul
log
respect
make
good
candid
target
galt
oral
coadminist
lct
addit
novel
chemic
formulationbas
strategi
target
drug
galt
could
lead
increas
target
effi
cienci
one
worth
mention
nanostructur
lipid
carrier
nlc
develop
success
sln
number
problem
identifi
ed
use
singl
type
solid
lipid
core
sln
led
format
crystallin
lattic
time
potenti
reduc
drugload
capac
gelat
sln
also
occur
prolong
storag
nlc
creat
way
reduc
problem
nlc
use
mixtur
solid
liquid
lipid
creat
imperfect
core
environ
space
accommod
drug
still
maintain
solid
state
therefor
said
nlc
secondgener
lipidbas
nanoparticl
formul
due
rel
new
develop
nlc
extens
studi
target
nlc
galt
research
begun
assess
target
potenti
one
work
studi
oral
administr
nlc
load
lipophil
vasodil
oral
administr
nlc
result
threefold
increas
bioavail
load
drug
compar
aqueou
suspens
suggest
nlc
activ
altern
absorpt
pathway
possibl
also
avoid
fi
rstpass
metabol
frequent
caus
low
oral
bioavail
mani
lipophil
drug
therefor
conceiv
immunomodul
load
nlc
target
toward
galt
similar
fashion
immunomodulatori
drug
advanc
treatment
protocol
wide
rang
disord
immun
system
activ
involv
rheumatoid
arthriti
multipl
sclerosi
howev
despit
consider
advanc
immunomodul
might
caus
seriou
advers
effect
could
caus
treatment
failur
therapi
system
advers
effect
promin
nontarget
administr
therefor
enhanc
deliveri
immunomodulatori
drug
immun
cell
potenti
reduc
system
advers
effect
well
improv
treatment
effi
caci
differ
approach
target
galt
immunomodulatori
drug
success
increas
concentr
drug
achiev
galt
importantli
signifi
cantli
enhanc
immunomodulatori
effect
immunomodulatori
drug
divers
physicochem
properti
target
galt
strategi
present
promis
new
way
treat
diseas
involv
immun
system
